1Which study tested CBT plus standard care for medication-resistant symptoms? Recall its nine-month findings & implication.
Kuipers et al. (1997): CBT + standard care for medication-resistant symptoms
At nine months: 50% responded vs 31% with standard care alone; one CBT participant worsened
Implication: supports an adjunctive benefit; not universal response
2How do the two 2014 studies differ in findings & design; & why is patient choice alone an inadequate explanation?
Jauhar et al. (2014): meta-analysis: small therapeutic effects; smaller with assessor masking
Morrison et al. (2014): trial: reduced symptoms in people not taking antipsychotics
Comparison limit: different samples & designs; patient choice alone cannot explain the difference
3Which 18-month follow-up distinguishes symptom improvement from relapse & rehospitalisation outcomes?
Tarrier et al. (2004): 18-month follow-up
Symptom benefit: but no significant group difference in relapse or rehospitalisation
Meaning: symptom reduction & relapse prevention are distinct outcomes
4What three questions should guide your overall judgement of CBT effectiveness?
Outcome-dependent effectiveness: ask what improved; for whom & for how long
Therapeutic effect: does not mean cure or prevention of every later episode
Essay contrast: short-term vs long-term effectiveness; symptoms vs relapse
5What does outcome-dependent effectiveness mean?
Effectiveness depends on what improved; for whom & for how long. Symptom reduction; relapse prevention & rehospitalisation are distinct outcomes. No significant difference does not establish identical effects.
6Evaluate CBT: Effectiveness.
1. A mixed picture: initial benefit
Kuipers et al. (1997): CBT + standard care for medication-resistant symptoms
At nine months: 50% responded vs 31% with standard care alone; one CBT participant worsened
Implication: supports an adjunctive benefit; not universal response
2. However: contrasting evidence
Jauhar et al. (2014): meta-analysis: small therapeutic effects; smaller with assessor masking
Morrison et al. (2014): trial: reduced symptoms in people not taking antipsychotics
Comparison limit: different samples & designs; patient choice alone cannot explain the difference
3. Furthermore: long-term outcomes
Tarrier et al. (2004): 18-month follow-up
Symptom benefit: but no significant group difference in relapse or rehospitalisation
Meaning: symptom reduction & relapse prevention are distinct outcomes
4. Overall judgement
Outcome-dependent effectiveness: ask what improved; for whom & for how long
Therapeutic effect: does not mean cure or prevention of every later episode
Essay contrast: short-term vs long-term effectiveness; symptoms vs relapse
Precision note: Corrections: “Jahur” -> Jauhar; the source’s patient-choice comparison is replaced with the study-design distinction. No significant difference ≠ identical effects.
7What evidence suggests CBT is acceptable to clients; vs potentially uncomfortable medical assessment?
Medical treatment & assessment: can sometimes feel frightening or uncomfortable
Kuipers et al. (1997): clients generally satisfied with CBT
Positive implication: an appropriate; acceptable way to address their problems
8How might referral decisions restrict access to CBT?
Restricted access: referral decisions made by psychiatrists
Perceived unsuitability: disbelief in diagnosis; or doing well on medication alone
Potential consequence: some individuals may miss access to a helpful intervention
9Which referral study involved 142 people? Give its percentage & explain what the figure measures.
Kingdon & Kirschen (2006)
142 diagnosed individuals: sample described in the notes
Only 49% referred: a referral figure; not a treatment-response rate
Raises a question: were appropriate patients being excluded?
10What balanced ethical judgement follows about CBT acceptability & access?
Equal access: to comprehensive treatment
Psychiatric prejudice?: one possible concern; not proven by the referral figure alone
Judgement: acceptability is a strength; access barriers may restrict who benefits
11Why must referral rate be distinguished from treatment-response rate?
Referral rate concerns how many people are directed to treatment. Treatment-response rate concerns how many improve. The 49% figure in Kingdon & Kirschen (2006) is a referral figure.
12Evaluate CBT: Ethical implications.
1. Regarding: acceptability
Medical treatment & assessment: can sometimes feel frightening or uncomfortable
Kuipers et al. (1997): clients generally satisfied with CBT
Positive implication: an appropriate; acceptable way to address their problems
2. A more significant concern
Restricted access: referral decisions made by psychiatrists
Perceived unsuitability: disbelief in diagnosis; or doing well on medication alone
Potential consequence: some individuals may miss access to a helpful intervention
3. Kingdon & Kirschen (2006)
Kingdon & Kirschen (2006)
142 diagnosed individuals: sample described in the notes
Only 49% referred: a referral figure; not a treatment-response rate
Raises a question: were appropriate patients being excluded?
4. Ethical implication
Equal access: to comprehensive treatment
Psychiatric prejudice?: one possible concern; not proven by the referral figure alone
Judgement: acceptability is a strength; access barriers may restrict who benefits
13Which historical audit reports unequal CBT availability? Recall the between-trust range & never-offered figure.
National Audit (2014): Royal College of Psychiatrists
Variation between trusts: 14%-67% of patients offered CBT; in the source
Around 50%: reported never being offered CBT
14Why does unequal access limit the societal benefits of CBT?
Guidance vs provision: recommended care may not reach everyone
Major disparities: location & service provision influence opportunity
Social implication: benefits cannot be universal when access is unequal
15Which study is cited for longer-term economic value; & how may initial costs be offset?
Kuipers et al. (1998): initial higher delivery costs
Offset over time: reduced reliance on emergency psychiatric services
Cost-effectiveness = benefits & savings considered across time
16Why can potential long-term savings coexist with limited CBT availability?
Trust budgets: prioritise immediate short-term care requirements
Long-term savings: may not solve today’s staffing & funding pressures
Judgement: potential cost-effectiveness can coexist with limited availability
17What does cost-effectiveness mean in this evaluation?
Considering treatment benefits & costs across time. Higher initial delivery costs may be offset by reduced reliance on emergency psychiatric services; this does not remove immediate funding pressures.
18Evaluate CBT: Societal implications.
1. Finally: unequal availability
National Audit (2014): Royal College of Psychiatrists
Variation between trusts: 14%-67% of patients offered CBT; in the source
Around 50%: reported never being offered CBT
2. Why does access matter?
Guidance vs provision: recommended care may not reach everyone
Major disparities: location & service provision influence opportunity
Social implication: benefits cannot be universal when access is unequal
3. Economically: longer-term value
Kuipers et al. (1998): initial higher delivery costs
Offset over time: reduced reliance on emergency psychiatric services
Cost-effectiveness = benefits & savings considered across time
4. Despite this: funding pressures
Trust budgets: prioritise immediate short-term care requirements
Long-term savings: may not solve today’s staffing & funding pressures
Judgement: potential cost-effectiveness can coexist with limited availability
Precision note: The audit percentages are historical figures from your notes; not claims about current service provision.